Table 4.
Univariate analysis of factors which may be associated with IFDs during antifungal prophylaxis
| Factor | Patients with no IFD (n = 107) | Patients with IFD (n = 23) | P-value |
|---|---|---|---|
| Posaconazole prophylaxis, no (%) | 59 (55.1) | 6 (26.9%) | 0.012 |
| Duration of neutropenia (days), mean ± SD | 23.5 ± 9.6 | 32.4 ± 14.3 | 0.0003 |
| Concomitant bloodstream infection, no (%) | 57 (53.2) | 18 (34.8) | 0.028 |
| Total dose of steroid (mg) | 80.8 ± 37.9 | 98.6 ± 32.7 | 0.038 |
| Intensive care unit admission, no (%) | 8 (7.5) | 8 (34.8) | 0.0015 |
| Secondary AML, no (%) | 33 (30.8) | 12 (52.2) | 0.051 |
| Receipt of total parenteral nutrition during hospitalization, no (%) | 2 (1.9) | 2 (8.7) | 0.14 |
| Chronic obstructive pulmonary disease, no (%) | 2 (1.9) | 2 (8.7) | 0.14 |
| Relapse, no (%) | 15 (14.0) | 2 (8.7) | 0.74 |
| Prior fungal colonization, no (%) | 5 (4.7) | 2 (8.7) | 0.61 |
| Presence of central lines, no (%) | 89 (83.2) | 21 (91.3) | 0.53 |
| Receipt of corticosteroids during hospitalization, no (%) | 102 (95.3) | 23 (100) | 0.59 |
| Age, mean ± SD | 59.5 ± 14.5 | 59.9 ± 14.8 | 0.90 |
| Mucositis during hospitalization, no (%) | 21 (19.6) | 1 (4.4) | 0.12 |
| Baseline CrCl <30 mL/min, no (%) | 9 (8.4) | 0 (0) | 0.36 |
| Acute renal failure (CrCl < 10 mL/min) during hospitalization, no (%) | 7 (6.5) | 2 (8.7) | 0.66 |
| Diabetes mellitus, no (%) | 18 (16.8) | 2 (8.7) | 0.53 |
| Male gender, no (%) | 70 (65.4) | 15 (65.2) | 0.99 |
| Total cytarabine received during this admission (mg), mean ± SD | 966.9 ± 1644.3 | 1183.1 ± 1832.2 | 0.58 |
IFD, possible, probable or definite invasive fungal disease; Cr Cl, creatinine clearance.